Literature DB >> 25396098

Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Allyson K Martínez1, Luca Maroni2, Marco Marzioni2, Syed T Ahmed3, Mena Milad4, Debolina Ray1, Gianfranco Alpini5, Shannon S Glaser5.   

Abstract

The liver has the amazing capacity to repair itself after injury; however, the same processes that are involved in liver regeneration after acute injury can cause serious consequences during chronic liver injury. In an effort to repair damage, activated hepatic stellate cells trigger a cascade of events that lead to deposition and accumulation of extracellular matrix components causing the progressive replacement of the liver parenchyma by scar tissue, thus resulting in fibrosis. Although fibrosis occurs as a result of many chronic liver diseases, the molecular mechanisms involved depend on the underlying etiology. Since studying liver fibrosis in human subjects is complicated by many factors, mouse models of liver fibrosis that mimic the human conditions fill this void. This review summarizes the general mouse models of liver fibrosis and mouse models that mimic specific human disease conditions that result in liver fibrosis. Additionally, recent progress that has been made in understanding the molecular mechanisms involved in the fibrogenic processes of each of the human disease conditions is highlighted.

Entities:  

Keywords:  hepatic fibrosis; hepatic stellate cell; murine model; primary biliary cirrhosis; primary sclerosing cholangitis

Year:  2014        PMID: 25396098      PMCID: PMC4226463          DOI: 10.1007/s40139-014-0050-2

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  127 in total

1.  Mechanism of early carbon tetrachloride toxicity in cultured rat hepatocytes.

Authors:  D E Johnston; C Kroening
Journal:  Pharmacol Toxicol       Date:  1998-12

2.  The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.

Authors:  E Jacquemin; J M De Vree; D Cresteil; E M Sokal; E Sturm; M Dumont; G L Scheffer; M Paul; M Burdelski; P J Bosma; O Bernard; M Hadchouel; R P Elferink
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

3.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria.

Authors:  K Hensley; Y Kotake; H Sang; Q N Pye; G L Wallis; L M Kolker; T Tabatabaie; C A Stewart; Y Konishi; D Nakae; R A Floyd
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

5.  Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Authors:  Sabine Oertelt; Zhe-Xiong Lian; Chun-Mei Cheng; Ya-Hui Chuang; Kerstien A Padgett; Xiao-Song He; William M Ridgway; Aftab A Ansari; Ross L Coppel; Ming O Li; Richard A Flavell; Mitchell Kronenberg; Ian R Mackay; M Eric Gershwin
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

Review 6.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis.

Authors:  January T Salas; Jesús M Banales; Sarai Sarvide; Sergio Recalde; Alex Ferrer; Iker Uriarte; Ronald P J Oude Elferink; Jesús Prieto; Juan F Medina
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

8.  Effects of prolonged (1 year) choline deficiency and subsequent re-feeding of choline on 1,2-sn-diradylglycerol, fatty acids and protein kinase C in rat liver.

Authors:  K A da Costa; S C Garner; J Chang; S H Zeisel
Journal:  Carcinogenesis       Date:  1995-02       Impact factor: 4.944

9.  Hepatocarcinogenesis by diethylnitrosamine in rats fed high dietary levels of lipotropes.

Authors:  L A Poirier
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

10.  Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice.

Authors:  Willy Hsu; Weici Zhang; Koichi Tsuneyama; Yuki Moritoki; William M Ridgway; Aftab A Ansari; Ross L Coppel; Zhe-Xiong Lian; Ian Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

View more
  10 in total

1.  Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.

Authors:  Todd R Harris; Sean Kodani; Amy A Rand; Jun Yang; Denise M Imai; Sung Hee Hwang; Bruce D Hammock
Journal:  Mol Pharmacol       Date:  2018-05-29       Impact factor: 4.436

Review 2.  Role of the blood coagulation cascade in hepatic fibrosis.

Authors:  Asmita Pant; Anna K Kopec; James P Luyendyk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-03       Impact factor: 4.052

Review 3.  Role of hemostatic factors in hepatic injury and disease: animal models de-liver.

Authors:  A K Kopec; N Joshi; J P Luyendyk
Journal:  J Thromb Haemost       Date:  2016-05-10       Impact factor: 5.824

4.  Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.

Authors:  So Yeon Kim; Kang Ho Kim; Jan M Schilling; Joseph Leem; Mehul Dhanani; Brian P Head; David M Roth; Alice E Zemljic-Harpf; Hemal H Patel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-21       Impact factor: 4.052

Review 5.  A Novel Perspective on the ApoM-S1P Axis, Highlighting the Metabolism of ApoM and Its Role in Liver Fibrosis and Neuroinflammation.

Authors:  Stefan Hajny; Christina Christoffersen
Journal:  Int J Mol Sci       Date:  2017-07-27       Impact factor: 5.923

6.  The Forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis.

Authors:  Hannah M Flood; Craig Bolte; Nupur Dasgupta; Akanksha Sharma; Yufang Zhang; Chandrashekhar R Gandhi; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Biol Open       Date:  2019-02-11       Impact factor: 2.422

7.  Dunaliella salina microalgae oppose thioacetamide-induced hepatic fibrosis in rats.

Authors:  Farouk K El-Baz; Abeer A A Salama; Rehab A Hussein
Journal:  Toxicol Rep       Date:  2019-11-10

8.  Clusterin Attenuates Hepatic Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Downregulating the Smad3 Signaling Pathway.

Authors:  Hye-Young Seo; So-Hee Lee; Ji-Ha Lee; Yu Na Kang; Young-Keun Choi; Jae Seok Hwang; Keun-Gyu Park; Byoung Kuk Jang; Mi-Kyung Kim
Journal:  Cells       Date:  2019-11-14       Impact factor: 6.600

Review 9.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

Review 10.  Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.

Authors:  Eline Geervliet; Ruchi Bansal
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.